Evidence map›Paper›PMID 38783264›Full record

ArticleBMC public health2024

Machine learning algorithms using national registry data to predict loss to follow-up during tuberculosis treatment.

Moreno M S Rodrigues, Beatriz Barreto-Duarte, Caian L Vinhaes, Mariana Araújo-Pereira, Eduardo R Fukutani, Keityane Bone Bergamaschi, Afrânio Kristki, Marcelo Cordeiro-Santos, Valeria C Rolla, Timothy R Sterling and 2 more

Abstract read
In one paragraph

Article in BMC public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Moreno M S RodriguesMultinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative, Salvador, Brazil. moreno.rodrigues@fiocruz.br.
Beatriz Barreto-DuarteMultinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative, Salvador, Brazil.
Caian L VinhaesMultinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative, Salvador, Brazil.
Mariana Araújo-PereiraMultinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative, Salvador, Brazil.
Eduardo R FukutaniMultinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative, Salvador, Brazil.
Keityane Bone BergamaschiLaboratório de Análise e Visualização de Dados, Fundação Oswaldo Cruz, Porto Velho, Brazil.
Afrânio KristkiPrograma de Pós-Graduação em Clínica Médica, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Marcelo Cordeiro-SantosFundação Medicina Tropical Doutor Heitor Vieira Dourado, Manaus, Brazil.
Valeria C RollaLaboratório de Pesquisa Clínica em Micobacteriose, Instituto Nacional de Infectologia Evandro Chagas, Fiocruz, Rio de Janeiro, Brazil.
Timothy R SterlingDivision of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA.
Artur T L QueirozMultinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative, Salvador, Brazil.
Bruno B AndradeMultinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative, Salvador, Brazil. bruno.andrade@fiocruz.br.

Funding

CCASAnet: Caribbean, Central and South America NetworkU01AI069923 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Pedro Enrique Cahn, Jessica L Castilho · 2006 to 2026
$41.6M
Regional Prospective Observational Research in Tuberculosis (RePORT) – Brazil NetworkU01AI172064 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BRUNO DE BEZERRIL ANDRADE, TIMOTHY R STERLING · 2023 to 2026
$4.0M
Conselho Nacional de Desenvolvimento Científico e Tecnológico Senior FellowshipCoordenação de Aperfeiçoamento de Pessoal de Nível Superior Finance code 001Fundação Oswaldo Cruz Programa Inova FIOCRUZ/Edital Inovação AmazôniaMinistério da Saúde 25029.000507/2013-07National Institute of Allergy and Infectious Diseases U01-AI069923NIAID NIH HHS U01 AI069923NIAID NIH HHS U01 AI172064
6 · The paper itself

Abstract

backgroundIdentifying patients at increased risk of loss to follow-up (LTFU) is key to developing strategies to optimize the clinical management of tuberculosis (TB). The use of national registry data in prediction models may be a useful tool to inform healthcare workers about risk of LTFU. Here we developed a score to predict the risk of LTFU during anti-TB treatment (ATT) in a nationwide cohort of cases using clinical data reported to the Brazilian Notifiable Disease Information System (SINAN).

methodsWe performed a retrospective study of all TB cases reported to SINAN between 2015 and 2022; excluding children (< 18 years-old), vulnerable groups or drug-resistant TB. For the score, data before treatment initiation were used. We trained and internally validated three different prediction scoring systems, based on Logistic Regression, Random Forest, and Light Gradient Boosting. Before applying our models we splitted our data into training (~ 80% data) and test (~ 20%) sets, and then compared the model metrics using the test data set.

resultsOf the 243,726 cases included, 41,373 experienced LTFU whereas 202,353 were successfully treated. The groups were different with regards to several clinical and sociodemographic characteristics. The directly observed treatment (DOT) was unbalanced between the groups with lower prevalence in those who were LTFU. Three models were developed to predict LTFU using 8 features (prior TB, drug use, age, sex, HIV infection and schooling level) with different score composition approaches. Those prediction scoring systems exhibited an area under the curve (AUC) ranging between 0.71 and 0.72. The Light Gradient Boosting technique resulted in the best prediction performance, weighting specificity and sensitivity. A user-friendly web calculator app was developed ( https://tbprediction.herokuapp.com/ ) to facilitate implementation.

conclusionsOur nationwide risk score predicts the risk of LTFU during ATT in Brazilian adults prior to treatment commencement utilizing schooling level, sex, age, prior TB status, and substance use (drug, alcohol, and/or tobacco). This is a potential tool to assist in decision-making strategies to guide resource allocation, DOT indications, and improve TB treatment adherence.

Indexed as

Lost to Follow-UpMachine LearningRegistriesTuberculosisAdolescentAdultAlgorithmsAntitubercular AgentsBrazilFemaleHumansMaleMiddle AgedRetrospective StudiesYoung AdultAntitubercular AgentsLoss to follow-upMachine learningScore predictionTuberculosis

Identifiers

PMID38783264
PMCPMC11112756

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.